Manufacturer of Controlled Substances; Notice of Application, 64677-64678 [E7-22515]
Download as PDF
<![CDATA[
64677
Federal Register / Vol. 72, No. 221 / Friday, November 16, 2007 / Notices
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Schedule
N-Ethylamphetamine (1475) ........................................................................................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ....................................................................................................................................................
4-Methoxyamphetamine (7411) ...................................................................................................................................................................
Amphetamine (1100) ...................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
Methylphenidate (1724) ...............................................................................................................................................................................
Pentobarbital (2270) ....................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
Hydromorphone (9150) ...............................................................................................................................................................................
Hydrocodone (9193) ....................................................................................................................................................................................
Methadone (9250) .......................................................................................................................................................................................
Methadone intermediate (9254) ..................................................................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Fentanyl (9801) ...........................................................................................................................................................................................
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex North Brunswick, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex North Brunswick,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22468 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22505 Filed 11–15–07; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 15, 2008.
Manufacturer of Controlled
Substances; Notice of Application
BILLING CODE 4410–09–P
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 6, 2007,
Cambridge Isotope Lab, 50 Frontage
VerDate Aug<31>2005
21:48 Nov 15, 2007
Jkt 214001
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on October 16, 2007,
Cody Laboratories, 601 Yellowstone
Avenue, Cody, Wyoming 82414, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Drug
Codeine (9050) .............................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Schedule
II
II
II
II
The company plans on manufacturing
the listed controlled substances in bulk
for sale to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than January 15, 2008.
E:\FR\FM\16NON1.SGM
16NON1
64678
Federal Register / Vol. 72, No. 221 / Friday, November 16, 2007 / Notices
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22515 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 26, 2007, and
published in the Federal Register on
July 3, 2007, (72 FR 36481), Dade
Behring, Inc., 100 GBC Drive, MS514,
Post Office Box 6101, Attention: RA/GS,
Newark, Delaware 19714–6101, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
Drug
Schedule
Tetrahydrocannabinols (7370) .....
Benzoylecgonine (9180) ...............
Morphine (9300) ...........................
I
II
II
mstockstill on PROD1PC66 with NOTICES
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls for DEA
exempt products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Dade
Behring, Inc. to manufacture the listed
basic class of controlled substance is
consistent with the public interest at
this time. DEA has investigated Dade
Behring, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22470 Filed 11–15–07; 8:45 am]
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
Importer of Controlled Substances;
Notice of Application
By Notice dated June 26, 2007, and
published in the Federal Register on
July 5, 2007, (72 FR 36729), Dade
Behring Inc., Regulatory Affairs, Quality
Systems, 20400 Mariani Avenue,
Cupertino, California 95014, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
Drug
Schedule
Tetrahydrocannabinols (7370) .....
Benzoylecgonine (9180) ...............
Morphine (9300) ...........................
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls for DEA
exempt products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Dade
Behring, Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Dade
Behring, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–22477 Filed 11–15–07; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
VerDate Aug<31>2005
21:48 Nov 15, 2007
Jkt 214001
I
II
II
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on June
22, 2007, Fisher Clinical Services Inc.,
7554 Schantz Road, Allentown,
Pennsylvania 18106, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Noroxymorphone (9668),
a basic class of controlled substance
listed in schedule II.
The company plans to import the
listed substance for analytical research
and clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, VA 22152; and must
be filed no later than December 17,
2007.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e) and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, (40 FR 43745–46), all applicants
for registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
E:\FR\FM\16NON1.SGM
16NON1
]]>Agencies
[Federal Register Volume 72, Number 221 (Friday, November 16, 2007)]
[Notices]
[Pages 64677-64678]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-22515]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on October 16, 2007, Cody
Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made
application by letter to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Codeine (9050)............................. II
Ecgonine (9180)............................ II
Hydrocodone (9193)......................... II
Morphine (9300)............................ II
------------------------------------------------------------------------
The company plans on manufacturing the listed controlled substances
in bulk for sale to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, VA 22152; and must be filed no later
than January 15, 2008.
[[Page 64678]]
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-22515 Filed 11-15-07; 8:45 am]
BILLING CODE 4410-09-P
